ERBB2 and cancer: Tumor suppressor PTEN was also more frequently mutated in the claudin-low group of ER-positive/HER2-negative/low proliferation cancers (10.5% versus 3.1% in luminal A cancers, Fisher’s exact test p = 0.04, Figure 3).